Pitolisant治疗OSA残余嗜睡的长期疗效与安全性
本研究为HAROSA 1和HAROSA 2两项随机对照试验的开放标签延续研究,纳入512例成人OSA患者,376例完成1年随访。结果显示,Pitolisant(最高20 mg/d)治疗1年可显著降低Epworth嗜睡量表评分(ITT人群平均差异-8.0,95%CI -8.3至-7.5),且安全性良好,未报告心血管安全问题。
要点
- Pitolisant可有效改善OSA患者日间嗜睡,持续1年。
- 无论是否使用CPAP,Pitolisant均显示长期疗效。
- 1年治疗安全性良好,无心脑血管安全信号。
核心结论
- Pitolisant可有效减轻成人OSA患者日间嗜睡,疗效持续1年。
- 无论患者是否接受CPAP治疗,Pitolisant均有效。
- Pitolisant治疗1年安全性良好,包括心血管安全性。
研究设计与样本
- HAROSA 1和HAROSA 2两项RCT的开放标签延续研究。
- 纳入两项RCT中所有成人患者(Pitolisant组和安慰剂组),共512例。
- 短期双盲阶段结束后(第13周起)给予Pitolisant,最高20 mg/d。
- 376例完成1年随访。
- 主要疗效终点为基线至第52周Epworth嗜睡量表评分变化。
主要发现
- ITT人群基线至1年Epworth嗜睡量表评分平均差异为-8.0(95%CI -8.3至-7.5)。
- 总体TEAE发生率为35.1%,严重TEAE为2.0%,特殊关注TEAE为11.1%。
- 初始Pitolisant组与安慰剂组间TEAE无显著差异。
- 未报告心血管安全问题。
关键数值与推荐
- Pitolisant剂量最高20 mg/d。
- 主要疗效终点为Epworth嗜睡量表评分从基线至第52周的变化。
- 安全性终点包括TEAE、严重TEAE和特殊关注TEAE。
临床怎么用
- 对于OSA患者经CPAP治疗后仍存在日间嗜睡,可考虑使用Pitolisant。
- 对于拒绝或不耐受CPAP的OSA嗜睡患者,Pitolisant可作为治疗选择。
- 长期使用Pitolisant需关注TEAE,但严重不良事件发生率低。
局限性
- 研究为开放标签设计,缺乏双盲对照。
- 仅376例完成1年随访,存在失访偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In people with OSA, excessive daytime sleepiness is a prominent symptom and can persist despite adherence to CPAP, the first-line therapy for OSA. Pitolisant was effective in reducing daytime sleepiness in two 12-week randomized controlled trials (RCTs), one in patients adherent to CPAP (BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS [HAROSA 1]) and the other in patients refusing or not tolerating CPAP (BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP [HAROSA 2]). RESEARCH QUESTION: Does the efficacy and safety of pitolisant persist when these patients take it long-term? STUDY DESIGN AND METHODS: All adults included in the HAROSA 1 and HAROSA 2 RCTs (both pitolisant and placebo arms) were offered pitolisant (up to 20 mg/d) after completion of the short-term double-anonymized phase (ie, from week 13) in an open-label cohort study. The primary efficacy outcome was the change in Epworth Sleepiness Scale score between baseline and week 52. Safety outcomes were treatment-emergent adverse event(s) (TEAE[s]), serious TEAEs, and special interest TEAEs. RESULTS: Out of 512 adults included in the two RCTs, 376 completed the 1-year follow-up. The pooled mean difference in Epworth Sleepiness Scale score from baseline to 1 year for the intention-to-treat sample was -8.0 (95% CI, -8.3 to -7.5). The overall proportions of TEAEs, serious TEAEs, and TEAEs of special interest were 35.1%, 2.0%, and 11.1%, respectively, without any significant difference between patients in the initial pitolisant and placebo arms. No cardiovascular safety issues were reported. INTERPRETATION: Pitolisant is effective in reducing daytime sleepiness over 1 year in adults with OSA, with or without CPAP treatment. Taken for 1 year, it has a good safety profile (including cardiovascular). TRIAL REGISTRATION: ClinicalTrials.gov; Nos.: NCT01071876 and NCT01072968; URL: www. CLINICALTRIALS: gov.
引用
- Pépin JL, Attali V, Caussé C, et al. Long-Term Efficacy and Safety of Pitolisant for Residual Sleepiness Due to OSA. Chest. 2023. PMID: 37979718. doi:10.1016/j.chest.2023.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。